
    
      Triple-negative breast cancer is associated with less treatment choices and shorter overall
      survival. Both vinorebine and oxaliplatin are effective in metastatic breast cancer. The
      investigators designed this trial to evaluate the combination of these two drugs in
      pretreated metastatic triple-negative breast cancer.
    
  